ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALMS is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has constructive technical support and insider buying, but it is still below the recent pivot, lacks a fresh AI Stock Picker or SwingMax buy signal, and the latest quarter remains deeply unprofitable. I would not call it a strong immediate buy at this price; it is better viewed as a hold/watch candidate until price and fundamentals confirm more durable momentum.
The trend is mixed to mildly constructive. MACD histogram is positive but contracting, which suggests momentum is still positive but weakening. RSI_6 at 38.26 is neutral-to-soft, not oversold enough to signal a strong rebound by itself. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports the broader trend. However, the current price at 23.52 is below the pivot at 24.683 and only slightly above support at 23.285, so the stock is near support rather than breaking out. The stock trend model suggests upside potential over the next day/week/month, but the current setup is not a high-conviction entry.
["Raymond James and Oppenheimer both issued very bullish post-data commentary, with price targets of 46 and 55 respectively.", "Recent Phase 3 psoriasis data for envudeucitinib was described by analysts as broadly competitive with major peers and favorable on safety.", "Insiders have been buying, with insider buying amount up 586.17% over the last month.", "Bullish moving average structure remains intact.", "Model-based stock trend suggests positive short-term and medium-term upside probabilities."]
["The stock sold off sharply in regular trading, down 6.82%, showing the market did not fully reward the recent news.", "No news in the recent week, so there is no fresh immediate catalyst beyond prior clinical readthroughs.", "H.C. Wainwright cut its price target from 40 to 25, citing a more competitive oral psoriasis market.", "The company is still posting large net losses and negative EPS.", "No recent congress trading data and no notable politician buying or selling.", "AI Stock Picker shows no signal today and SwingMax has no recent signal."]
In Q4 2025, revenue was 1.93 million, flat year over year, while net income was -92.93 million and EPS was -0.89, both still deeply negative. Gross margin was 100, but the key takeaway is that the latest quarter did not show meaningful top-line growth and profitability remains far away. For a beginner long-term investor, the financial profile still looks speculative rather than fundamentally established.
Analyst sentiment is broadly positive but mixed on valuation and competition. Raymond James initiated/kept a Strong Buy view and Oppenheimer raised its target to 55, both pointing to strong confidence in the clinical story and competitive positioning. Morgan Stanley also raised its target to 38 and kept Overweight. The main bearish note came from H.C. Wainwright, which cut its target to 25 because the oral psoriasis market appears more competitive. Overall, Wall Street leans bullish, but not unanimously, and the recent target changes show strong upside expectations tempered by competitive concerns.
